ABUS vs SNYR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABUS Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while SNYR counters with relative strength in Valuation. Fundamentally, ABUS trades at 10.2x Forward P/E with 80.1% operating margin (-43.5% YoY revenue) versus SNYR at 0.6x Forward P/E and -10.3% operating margin (-32.8% YoY). In options structure, ABUS sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro) against SNYR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ABUS Revenue | SNYR Revenue | ABUS Op. Margin | SNYR Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $10M | $30M | -1510.2% | -14.5% | SNYR |
| FY2019 | $10M | $30M | -2394.0% | -27.1% | SNYR |
| FY2020 | $10M | N/A | -836.1% | N/A | ABUS |
| FY2021 | $10M | N/A | -669.1% | N/A | ABUS |
| FY2022 | $40M | N/A | -167.8% | N/A | ABUS |
| FY2023 | $20M | $40M | -430.5% | 25.3% | SNYR |
| FY2024 | $10M | $30M | -1236.7% | 16.7% | SNYR |
| FY2025 | $10M | $30M | -271.0% | -27.8% | SNYR |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABUS | SNYR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $623.9M | $4.1M | Larger Scale | ABUS |
| Trailing P/E Ratio Valuation | 3.6x | 0.6x | Lower Multiple | SNYR |
| Forward P/E Ratio Valuation | 10.2x | 0.6x | Lower Multiple | SNYR |
| Revenue Growth (YoY) Growth | -43.5% | -32.8% | Higher Growth | SNYR |
| Operating Margin (TTM) Profitability | 80.1% | -10.3% | Higher Margin | ABUS |
| Net Profit Margin Profitability | 121.2% | -57.0% | Higher Margin | ABUS |
| Return on Equity (ROE) Capital Efficiency | 269.6% | -361.1% | Higher ROE | ABUS |
| 52-Week Range Position Momentum | 27% ($4โ$5) | 1% ($0โ$3) | Stronger Trend | ABUS |
| Beta / 30D Volatility Risk Regime | 1.04ฮฒ ยท 48% Vol | -0.86ฮฒ ยท 868% Vol | Lower Realized Risk | ABUS |
| Unified Institutional Score Composite Signal | 43.4 / 100 (HOLD) | 48.9 / 100 (HOLD) | Higher Composite | SNYR |